Why Genmab A/S’s (GMAB) Stock Is Up 14.78%
As of Wednesday, October 28, Genmab A/S’s GMAB share price has surged by 14.78%, which has investors questioning if this is right time to sell.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter’s syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
Commentary & Analysis
Why Genmab A/S’s (GMAB) Stock Is Up 6.51%
As of Friday, October 23, Genmab A/S’s GMAB share price has surged by 6.51%, which has investors questioning if this is right time to sell.Jenna Brashear
Is Genmab A/S (GMAB) Overvalued?
We dive into why Genmab A/S (GMAB) could be considered overvalued on 2026-07-21, based on AAII’s Value Score and Grade.Tudor Pop
Why Genmab A/S’s (GMAB) Stock Is Up 6.46%
As of Tuesday, June 30, Genmab A/S’s GMAB share price has surged by 6.46%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Genmab A/S’s (GMAB) Stock Is Down 5.60%
As of Tuesday, June 02, Genmab A/S’s GMAB share price has dipped by 5.60%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Financial Summary
| Share Statistics | GMAB | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $33,637.4 | $224.9 | 91% |
|
| Shares Out (Mil) | 62.1 | 54.9 | 52% |
|
| Institutional Ownership | 98.1% | 92.8% | 77% |
|
| Float (Mil) | 58.9 | 42.5 | 50% |
|
| Beta | 0.52 | 0.97 | 29% |
|
| Avg Daily Volume (000s) | 5,101 | 529 | 91% |
|
| Price Change (52-week) |
85.4% | 45.5% | 93% |
|
| Growth | GMAB | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 17.5% | 13.6% | 78% |
|
| Net Income (5yr) | 4.3% | (10.3%) | 46% |
|
| EPS (5yr) | 5.3% | 15.8% | 39 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (37.6%) | (15.7%) | 13% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | $0.333 | $1.249 | $1.763 | |
| Month Ago EPS | $3.503 | $12.211 | $16.711 | |
| # Rev Up | 1 | 0 | 1 | |
| # Rev Down | 0 | 1 | 0 | |
| Three Months Ago EPS | $3.503 | $11.649 | $16.157 | |
| Year/Year Chg | (94.0%) | (91.9%) | (80.5%) | |
| Financials | GMAB | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $4,296 | $41 | 72% |
|
| Net Income (TTM) (Mil) | $729 | ($43) | 82% |
|
| EPS (TTM) | $11.858 | ($1.500) | 95% |
|
| Operating Cash Flow (TTM) (Mil) | $875 | ($35) | 78% |
|
| Net Cash Flow (TTM) (Mil) | $99 | $-0 | 78% |
|
| Long-Term Debt (Q1) (Mil) | $4,850 | $4 | 85% |
|
| Enterprise Value (Q1) (Mil) | $36,621 | $160 | 90% |
|
| Valuation | GMAB | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.54 | 2.09 | 11% |
|
| P/E | 4.6 | 17.5 | 4% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 0.9 | 1.0 | 42% |
|
| Ratios | GMAB | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 92.7% | 67.8% | 94% |
|
| Net Margin | 17.0% | (53.7%) | 75% |
|
| ROA | 7.3% | (47.4%) | 79% |
|
| ROE | 12.1% | (51.9%) | 63% |
|
| Liabilities to Assets | 51.0% | 29.6% | 44% |
|
| F-Score | 4 | 3 | 34% |
|
Passing Stock Screens
As of 11/11/2026, from a list of 60 stock screening strategies,
FACTOR STRATEGY
ADR Screen
Factors: Value, Momentum
An ADR stock screen seeks out foreign companies with attractive PEG ratios and increasing price strength.
| Performance Since Inception: | 6.3% |
| +/- S&P 500: | -1.1 |
GURU STRATEGY
Fisher (Philip) Screen
Factors: Value, Growth
A perspective on the evolution of the investment philosophy of a successful money manager who learned from his mistakes.
| Performance Since Inception: | 5.7% |
| +/- S&P 500: | -1.7 |
Passing Stocks
| Genmab A/S | GMAB |
| Harmony Biosciences Holdings, Inc. | HRMY |
| Sterling Infrastructure, Inc. | STRL |
| Stride, Inc. | LRN |
GURU STRATEGY
Kirkpatrick Bargain Screen
Factors: Value, Momentum
Investing model outlined in Charles Kirkpatrick's book, Beat the Market: Invest by Knowing What Stocks to Buy and What Stocks to Sell.
| Performance Since Inception: | 6.9% |
| +/- S&P 500: | -0.5 |
